On February 26, 2023, Susannah Gray was appointed by the Board of Directors of Theravance Biopharma, Inc. to serve as a Class II member of the Board of Directors. The Company's Board of Directors has determined that Susannah Gray is independent within the meaning of the independent director standards of the Securities and Exchange Commission and Nasdaq. Susannah Gray served as the Executive Vice President and Chief Financial Officer of Royalty Pharma from January 2005 to December 2018.

She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector in CIBC World Markets' high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). She currently serves on the Boards of Directors of Maravai LifeSciences, 4D Molecular Therapeutic and Morphic Therapeutic.

Previously, Ms. Gray served on the Board of Directors of Apria until its sale to Owens & Minor. Ms. Gray received a BA, with honors, from Wesleyan University and an MBA from Columbia University. In addition, on February 26, 2023, William D. Young decided not to stand for re-election as a director at the Company's next annual general meeting of shareholders.

The decision is not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.